Oncomed Pharmaceuticals Inc patents (2016 archive)

Tigit-binding agents and uses thereof

Agents that specifically bind tigit are disclosed. The tigit-binding agents may include polypeptides, antibodies, and/or bispecific agents. ... Oncomed Pharmaceuticals Inc

Compositions and methods for diagnosing and treating cancer

An isolated antibody that specifically binds to an extracellular domain of human dll4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-dll4 antibody.. ... Oncomed Pharmaceuticals Inc

Polynucleotides encoding vegf/dll4 binding agents

The present invention relates to vegf-binding agents, dll4-binding agents, vegf/dll4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human vegf, antibodies that specifically bind human dll4, and bispecific antibodies that specifically bind human vegf and/or human dll4. ... Oncomed Pharmaceuticals Inc

Methods and monitoring of treatment with a wnt pathway inhibitor

Methods for treating diseases such as cancer comprising administering a wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.. . ... Oncomed Pharmaceuticals Inc

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. ... Oncomed Pharmaceuticals Inc

Methods and monitoring of treatment with a dll4 antagonist

Methods for treating diseases such as cancer comprising administering a dll4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.. . ... Oncomed Pharmaceuticals Inc

Frizzled-binding agents and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. ... Oncomed Pharmaceuticals Inc

Methods for treating cancer with dll4 antagonists

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a dll4 antagonist.. ... Oncomed Pharmaceuticals Inc

Met-binding agents and uses thereof

The present invention relates to binding agents that specifically bind human met, binding agents that specifically bind one or more components of the wnt pathway, bispecific agents that bind both human met and one or more components of the wnt pathway, and methods of using the agents for treating diseases such as cancer.. . ... Oncomed Pharmaceuticals Inc

Identification of predictive biomarkers associated with wnt pathway inhibitors

The present invention provides biomarkers for identifying tumors likely to respond to treatment with wnt pathway inhibitors. Also provided are methods for identifying tumors and/or patients that are likely to be responsive or non-responsive to treatment with a wnt pathway inhibitor. ... Oncomed Pharmaceuticals Inc

Method for making heteromultimeric molecules

Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.. ... Oncomed Pharmaceuticals Inc

Tnfrsf-binding agents and uses thereof

Polypeptides and agents that bind a tnf receptor superfamily protein are disclosed, particularly agents that specifically bind gitr, ox40, or cd40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising gitrl, ox40l, or cd40l and/or bispecific agents. ... Oncomed Pharmaceuticals Inc

Methods for treating cancers comprising k-ras mutations

Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a k-ras mutation. ... Oncomed Pharmaceuticals Inc

Methods of treating neuroendocrine tumors using frizzled-binding agents

Novel methods of treating neuroendocrine tumors are provided. In one embodiment, the method comprises administering to a subject in need thereof a therapeutically effective dose of a wnt antagonist. ... Oncomed Pharmaceuticals Inc